Welcome to BioSeeker Group!

Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Additional Information

Published Date Dec 19, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1617
PDF Fact Sheet View Fact Sheet for the report Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $2,450.00

Special Price: $1,225.00

Quick Overview

This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others.

    To find out more about Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have apoptosis-modulating properties.This report includes both direct apoptogen targets (apoptosis-related targets) and indirect apoptogen targets (non-apoptotic targets which nevertheless have apoptotic effects).

This report comprises defined and up to date development strategies for 234 apoptotic drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the apoptotic drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:
* The identified competitive landscape of apoptotic drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 41 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the apoptotic drugs in general.

* Almost nine out of every ten drug target strategies in Phase III development are new to apoptotic drugs, whereas almost seven out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Phase II (26%) and Phase I (19%) development.

* Small molecule, Nucleic Acid and Antibody drugs are the dominating compound strategies of apoptotic cancer drugs, which represent more than 80% of the entire pipeline.

* Antibody based apoptotic cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of small molecules and nucleic acid therapies.

* The highest number of described target strategies among apoptotic drugs are found in non-small cell lung cancer, breast cancer and prostate cancer.

* Apoptotic drugs are experiencing targeting competition in four out of every ten cancer indications described, and more so in non-hodgkin’s lymphoma, prostate cancer and pancreatic cancer.

* The highest number of described drug target strategies of apoptotic drugs belongs to Novartis, EpiCept, Johnson & Johnson and Pfizer.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any apoptotic drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 22
4.2 List of Tables 22
5 Introduction 33
5.1 The Scope of this Report 33
5.2 Definitions 36
5.3 Abbreviations 36
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 37
6.1 Drug Repositioning in Oncology 37
6.2 Introduction to Targets of Apoptotic Drugs in Oncology 38
6.2.1 Auxiliary Transport Protein Activity Targets 45
6.2.2 Carboxy-lyase Activity Targets 46
6.2.3 Caspase Activator Activity Targets 48
6.2.4 Catalytic Activity Targets 49
6.2.5 Cell Adhesion Molecule Activity Targets 59
6.2.6 Chaperone Activity Targets 65
6.2.7 Complement Activity Targets 70
6.2.8 Cysteine-type Peptidase Activity Targets 72
6.2.9 Cytokine Activity Targets 79
6.2.10 Deacetylase Activity Targets 81
6.2.11 DNA Binding Targets 82
6.2.12 DNA Topoisomerase Activity Targets 83
6.2.13 G-protein Coupled Receptor Activity Targets 87
6.2.14 Glutathione Transferase Activity Targets 91
6.2.15 Growth Factor Activity Targets 93
6.2.16 Growth Factor Binding Targets 95
6.2.17 GTPase Activator Activity Targets 96
6.2.18 GTPase Activity Targets 97
6.2.19 Hydrolase Activity Targets 106
6.2.20 Kinase Activity Targets 108
6.2.21 Kinase Binding Targets 121
6.2.22 Kinase Regulator Activity Targets 125
6.2.23 Ligand-dependent Nuclear Receptor Activity Targets 130
6.2.24 Ligase Activity Targets 133
6.2.25 Lipid Kinase Activity Targets 139
6.2.26 Metallopeptidase Activity Targets 146
6.2.27 Molecular Function Unknown Targets 148
6.2.28 Motor Activity Targets 152
6.2.29 Oxidoreductase Activity Targets 154
6.2.30 Peptide Hormone Targets 156
6.2.31 Phosphoric Diester Hydrolase Activity Targets 157
6.2.32 Protein Binding Targets 160
6.2.33 Protein Serine/Threonine Kinase Activity Targets 164
6.2.34 Protein-tyrosine Kinase Activity Targets 206
6.2.35 Receptor Activity Targets 219
6.2.36 Receptor Binding Targets 240
6.2.37 Receptor Signaling Complex Scaffold Activity Targets 245
6.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 257
6.2.39 RNA Binding Targets 258
6.2.40 Serine-type Peptidase Activity Targets 259
6.2.41 Structural Constituent of Cytoskeleton Targets 260
6.2.42 Structural Molecule Activity Targets 262
6.2.43 Superoxide Dismutase Activity Targets 263
6.2.44 T Cell Receptor Activity Targets 266
6.2.45 Transcription Factor Activity Targets 267
6.2.46 Transcription Regulator Activity Targets 285
6.2.47 Transferase Activity Targets 299
6.2.48 Translation Regulator Activity Targets 301
6.2.49 Transmembrane Receptor Activity Targets 305
6.2.50 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 309
6.2.51 Transporter Activity Targets 335
6.2.52 Ubiquitin-specific Protease Activity Targets 340
6.2.53 Other Targets 342
6.3 The Cancer Genome Project and Targets of Apoptotic Drugs in Oncology 347
6.3.1 Targets of Apoptotic Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 347
6.4 Apoptotic Therapeutics is Stimulated by Available Structure Data on Targets 352
6.5 Target-Target Interactions among Identified Targets of Apoptotic Drugs in Oncology 356
6.6 The Drug-Target Competitive Landscape 360
6.7 Protein Expression Levels of Identified Targets of Apoptotic Drugs in Oncology 364
6.8 Pathway Assessment of Apoptotic Drugs in Oncology 367
6.8.1 Tools for Analysis of Cancer Pathways 368
6.8.2 Pathway Assessment 369
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development 417
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Apoptotic Drugs in Oncology 419
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Apoptotic Drugs in Oncology 420
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Apoptotic Drugs in Oncology 422
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Apoptotic Drugs in Oncology 426
7.5 Preclinical Development: New and Unique Drug Target Strategies of Apoptotic Drugs in Oncology 431
7.6 Drug Target Strategies of No Data, Suspended or Terminated Apoptotic Drugs in Oncology 434
7.7 Target Strategy Development Profiles of Apoptotic Drugs in Oncology 437
7.7.1 Marketed 441
7.7.2 Pre-registration 446
7.7.3 Phase III 448
7.7.4 Phase II 472
7.7.5 Phase I 521
7.7.6 Preclinical 553
7.7.7 Suspended 580
7.7.8 Ceased 582
7.8 The Competition Through Close Mechanistic Approximation of Apoptotic Drugs in Oncology 619
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy 623
8.1 Small Molecules 625
8.1.1 Background 625
8.1.2 Target Strategies of Small Molecule Drugs 626
8.2 Peptide & Protein Drugs 637
8.2.1 Background 637
8.2.2 Target Strategies of Peptide and Protein Drugs 638
8.3 Antibodies 642
8.3.1 Background 642
8.3.2 Target Strategies of Antibody Drugs 642
8.4 Nucleic Acid Therapies 645
8.4.1 Background 645
8.4.2 Target Strategies of Nucleic Acid Drugs 646
8.5 Gene Therapy 649
8.5.1 Background 649
8.5.2 Target Strategies of Gene Therapy Drugs 649
8.6 Drug Delivery and Nanotechnology 652
8.6.1 Background 652
8.6.2 Target Strategies of Reformulated Drugs 652
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 654
9 Selecting Indication for Apoptotic Drugs in Oncology 661
9.1 Acute Lymphocytic Leukemia 664
9.2 Acute Myelogenous Leukemia 666
9.3 Adrenal Cancer 668
9.4 B-cell Lymphoma 669
9.5 Basal Cell Cancer 671
9.6 Biliary Cancer 672
9.7 Bladder Cancer 673
9.8 Bone Cancer 675
9.9 Brain Cancer 676
9.10 Breast Cancer 678
9.11 Cancer (general) 681
9.12 Cancer Diagnosis 682
9.13 Carcinoid 683
9.14 Cervical Cancer 684
9.15 Cervical Dysplasia 685
9.16 Chemopreventative 686
9.17 Chemotherapy-induced Pain 687
9.18 Chronic Lymphocytic Leukemia 688
9.19 Chronic Myelogenous Leukemia 691
9.20 Chronic Myelomonocytic Leukemia 693
9.21 Colorectal Cancer 694
9.22 Endometrial Cancer 697
9.23 Fallopian Tube Cancer 699
9.24 Fibro Sarcoma 700
9.25 Gastrointestinal Cancer (general) 701
9.26 Gastrointestinal Stomach Cancer 702
9.27 Gastrointestinal Stromal Cancer 704
9.28 Head and Neck Cancer 705
9.29 Hematological Cancer (general) 707
9.30 Hodgkin’s Lymphoma 708
9.31 Leiomyo Sarcoma 710
9.32 Leukemia (general) 711
9.33 Lipo Sarcoma 712
9.34 Liver Cancer 713
9.35 Lung Cancer (general) 715
9.36 Lymphoma (general) 718
9.37 Mastocytosis 720
9.38 Melanoma 721
9.39 Mesothelioma 724
9.40 Myelodysplastic Syndrome 725
9.41 Myeloma 727
9.42 Nasopharyngeal Cancer 730
9.43 Neuroblastoma 730
9.44 Neuroendocrine Cancer (general) 731
9.45 non-Hodgkin’s Lymphoma 732
9.46 Non-Small Cell Lung Cancer 735
9.47 Oesophageal Cancer 738
9.48 Oral Cancer 739
9.49 Osteo Sarcoma 740
9.50 Ovarian Cancer 741
9.51 Pancreatic Cancer 744
9.52 Peritoneal Cancer 747
9.53 Prostate Cancer 748
9.54 Radio/chemotherapy-induced Alopecia 752
9.55 Radio/chemotherapy-induced Anemia 752
9.56 Radio/chemotherapy-induced Bone Marrow Injury (general) 753
9.57 Renal Cancer 754
9.58 Rhabdomyo Sarcoma 757
9.59 Sarcoma (general) 758
9.60 Small Cell Lung Cancer 760
9.61 Soft Tissue Sarcoma 762
9.62 Solid Tumor 764
9.63 Squamous Cell Cancer 766
9.64 T-cell Lymphoma 767
9.65 Testicular Cancer 768
9.66 Thymoma Cancer 769
9.67 Thyroid Cancer 770
9.68 Unspecified Cancer Indication 772
9.69 Waldenstrom’s hypergammaglobulinemia 776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator 777
10.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 781
10.2 Company Facts and Ranking 783
10.3 Competitive Fall-Out Assessment 789
10.4 Abbott 791
10.5 Access 797
10.6 Advanced Life Sciences 801
10.7 AEgera 805
10.8 AEterna Zentaris 813
10.9 Aida Pharmaceuticals 820
10.10 Aileron Therapeutics 825
10.11 Alnylam 829
10.12 Ambrilia Biopharma 833
10.13 Amgen 837
10.14 Anadys Pharmaceuticals 844
10.15 Anaphore 848
10.16 Anavex Life Sciences 854
10.17 Antisoma 859
10.18 Aphios 865
10.19 Apogenix 869
10.20 ApopLogic Pharmaceuticals 873
10.21 Arno Therapeutics 880
10.22 ArQule 884
10.23 Ascenta Therapeutics 892
10.24 Astex Therapeutics 898
10.25 AstraZeneca 902
10.26 Attenuon 906
10.27 Avila Therapeutics 911
10.28 Basilea Pharmaceutica 915
10.29 Bayer 922
10.30 BioAlliance Pharma 930
10.31 BioAxone 934
10.32 Biocad 938
10.33 Biogen Idec 944
10.34 BioInvent 950
10.35 BioLineRx 954
10.36 Biomas 958
10.37 Bionovo 962
10.38 BioVex 966
10.39 Boehringer Ingelheim 970
10.40 Bristol-Myers Squibb 976
10.41 Cancer Research Technology 981
10.42 CDG Therapeutics 985
10.43 Celera 989
10.44 Cephalon 993
10.45 ChemoCentryx 998
10.46 Chlorogen 1002
10.47 Chroma Therapeutics 1006
10.48 Cleveland BioLabs 1010
10.49 CombinatoRx 1015
10.50 Coronado Biosciences 1020
10.51 Critical Outcome Technologies 1026
10.52 Curis 1030
10.53 Cyclacel 1034
10.54 Cylene Pharmaceuticals 1040
10.55 Cynvec 1045
10.56 CytImmune Sciences 1049
10.57 Cytochroma 1055
10.58 CytRx 1059
10.59 Daewoong 1063
10.60 Daiichi Sankyo 1067
10.61 Dainippon Sumitomo Pharma 1073
10.62 DeveloGen 1077
10.63 Eisai 1083
10.64 Eleos 1088
10.65 Eli Lilly 1092
10.66 Emergent BioSolutions 1099
10.67 EntreMed 1103
10.68 EpiCept 1109
10.69 Erimos 1117
10.70 Exelixis 1122
10.71 Genta 1128
10.72 Gerolymatos 1134
10.73 Geron 1138
10.74 GlaxoSmithKline 1143
10.75 GlycoGenesys 1150
10.76 Glycotope 1155
10.77 GPC Biotech 1159
10.78 Green Cross 1163
10.79 Harbor BioSciences 1167
10.80 Hoffmann-La Roche 1171
10.81 Human Genome Sciences 1177
10.82 Idera Pharmaceuticals 1184
10.83 Infinity Pharmaceuticals 1188
10.84 Innate Pharma 1194
10.85 InNexus Biotechnology 1198
10.86 Inovio 1203
10.87 Insmed 1207
10.88 Insys Therapeutics 1211
10.89 Intradigm 1215
10.90 Introgen Therapeutics 1219
10.91 Isis Pharmaceuticals 1225
10.92 ISU ABXIS 1229
10.93 Johnson & Johnson 1233
10.94 Kalypsys 1241
10.95 Keryx Biopharmaceuticals 1248
10.96 Kyowa Hakko Kirin 1254
10.97 Leo 1260
10.98 Ligand 1264
10.99 Lorus Therapeutics 1269
10.100 Medisyn Technologies 1273
10.101 Merck & Co 1277
10.102 MethylGene 1281
10.103 Nereus Pharmaceuticals 1286
10.104 Nerviano Medical Sciences 1291
10.105 NIH – The US National Institute of Health 1295
10.106 Nippon Shinyaku 1299
10.107 Non-industrial Source 1304
10.108 Novacea 1308
10.109 NovaLead 1313
10.110 Novartis 1319
10.111 Novelix 1336
10.112 Novogen 1340
10.113 Onconova 1347
10.114 Oncothyreon 1353
10.115 OSI Pharmaceuticals 1358
10.116 OXiGENE 1364
10.117 PanaGin 1369
10.118 Patrys 1373
10.119 Pfizer 1377
10.120 Pharmacyclics 1384
10.121 PharmaMar 1390
10.122 Pharminox 1397
10.123 Pierre Fabre 1401
10.124 ProMetic Life Sciences 1405
10.125 QLT 1411
10.126 Reata Pharmaceuticals 1417
10.127 Regulon 1425
10.128 Rigel 1429
10.129 Rosetta Genomics 1435
10.130 Sanofi 1439
10.131 Santaris Pharma 1445
10.132 SBI Biotech 1452
10.133 Seattle Genetics 1456
10.134 Semafore Pharmaceuticals 1461
10.135 Senesco Technologies 1466
10.136 Sigma-Tau 1471
10.137 SRI International 1475
10.138 SuperGen 1481
10.139 Switch Pharma 1488
10.140 SymBio Pharmaceuticals 1492
10.141 Symbiotec 1496
10.142 Takeda 1500
10.143 Taxolog 1507
10.144 Telik 1513
10.145 TetraLogic Pharmaceuticals 1518
10.146 Teva 1522
10.147 Thallion Pharmaceuticals 1526
10.148 Tigris Pharmaceuticals 1530
10.149 TopoTarget 1535
10.150 Tracon Pharmaceuticals 1545
10.151 UMN Pharma 1551
10.152 ValiRx 1555
10.153 VBL Therapeutics 1561
10.154 Velacor Therapeutics 1565
10.155 Vertex Pharmaceuticals 1569
10.156 Vical 1573
10.157 VioQuest 1577
10.158 Viragen 1583
10.159 Viralytics 1587
10.160 ViroTarg 1591
10.161 VM Discovery 1596
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Apoptotic Drugs in Oncology 359
Figure 2: The Drug-Target Competitive Landscape of Apoptotic Drugs in Oncology - Large Cluster 361
Figure 3: The Drug-Target Competitive Landscape Apoptotic Drugs in Oncology - Smaller Clusters 362
Figure 4: Head-to-Head Targeting Competitive Landscape of Apoptotic Drugs in Oncology 363
Figure 5: Distribution of Compound Strategies among Apoptotic Cancer Drugs 654
Figure 6: Primary Sub-cellular Localization of Drug Targets 655
Figure 7: Number of Companies per Ranking Level 783

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Apoptotic Drug Pipeline in Oncology by Stage of Development 33
Table 3: Head to Head Target Competition among Apoptotic Drugs in Oncology 33
Table 4: Overview of Drug Target Strategy Themes 38
Table 5: Terminally Ceased Targets of Apoptotic Drugs in Oncology 39
Table 6: Official Gene Name to Target Profle 40
Table 7: Targets of Apoptotic Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 348
Table 8: Identity of Drug Targets with Available Biological Structures 352
Table 9: Number of Target-Target Interactions among Targets of Apoptotic Drugs in Oncology 357
Table 10: Available Protein Expression Profiles of Apoptotic Drug Targets in Oncology 364
Table 11: Pathway Summary 369
Table 12: Drug Targets without any Identified Assigned Pathways 369
Table 13: Pathway Profiles According to BioCarta of Apoptotic Drug Targets in Oncology 371
Table 14: Pathway Profiles According to KEGG of Apoptotic Drug Targets in Oncology 389
Table 15: Pathway Profiles According to NetPath of Apoptotic Drug Targets in Oncology 409
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 417
Table 17: Top Competitive Target Strategies of Apoptotic Drugs in Oncology 418
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Apoptotic Drugs in Oncology 419
Table 19: The Competition Through Close Mechanistic Approximation Between Apoptotic Drugs in Oncology being Marketed or in Pre-registration 419
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Apoptotic Drugs in Oncology 420
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Apoptotic Drugs in Oncology 421
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Apoptotic Drugs in Oncology 422
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Apoptotic Drugs in Oncology 425
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Apoptotic Drugs in Oncology 426
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Apoptotic Drugs in Oncology 429
Table 26: New and Unique Target Strategies in Preclinical Development of Apoptotic Drugs in Oncology 431
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Apoptotic Drugs in Oncology 433
Table 28: Target Strategies of No Data, Suspended and Terminated Apoptotic Drugs in Oncology 434
Table 29: Connecting Target Strategy with Its Profile Identification Number 437
Table 30: The Competition Through Close Mechanistic Approximation Among Apoptotic Drugs in Oncology 619
Table 31: Overview of Compound Strategy Competition Among Apoptotic Cancer Drugs 624
Table 32: Overview of the Competitive Landscape of Small Molecule Based Apoptotic Cancer Drugs 626
Table 33: Competitive Comparison of Target Strategies of Small Molecule Apoptotic Cancer Drugs 627
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Apoptotic Cancer Drugs 630
Table 35: Overview of the Competitive Landscape of Peptide Based Apoptotic Cancer Drugs 638
Table 36: Competitive Comparison of Target Strategies of Peptide Based Apoptotic Cancer Drugs 639
Table 37: Pursued Target Strategies of Peptide Based Apoptotic Cancer Drugs 639
Table 38: Overview of the Competitive Landscape of Protein Based Apoptotic Cancer Drugs 640
Table 39: Competitive Comparison of Target Strategies of Protein Based Apoptotic Cancer Drugs 641
Table 40: Pursued Target Strategies of Protein Based Apoptotic Cancer Drugs 641
Table 41: Overview of the Competitive Landscape of Antibody Based Apoptotic Cancer Drugs 642
Table 42: Competitive Comparison of Target Strategies of Antibody Based Apoptotic Cancer Drugs 643
Table 43: Pursued Target Strategies of Antibody Based Apoptotic Cancer Drugs 644
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Apoptotic Cancer Drugs 646
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Apoptotic Cancer Drugs 647
Table 46: Pursued Target Strategies of Nucleic Acid Based Apoptotic Cancer Drugs 647
Table 47: Vectors in Gene Therapy 649
Table 48: Overview of the Competitive Landscape of Gene Therapy Based Apoptotic Cancer Drugs 649
Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Apoptotic Cancer Drugs 650
Table 50: Pursued Target Strategies of Gene Therapy Based Apoptotic Cancer Drugs 651
Table 51:Overview of the Competitive Landscape of Reformulated Apoptotic Cancer Drugs 652
Table 52: Pursued Target Strategies of Reformulated Apoptotic Cancer Drugs 653
Table 53: Compound Strategies based on Sub-Cellular Localization of Apoptotic Cancer Drug Targets 655
Table 54 Competitive Summary by Cancer Indication of Apoptotic Drugs 662
Table 55: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Acute Lymphocytic Leukemia 664
Table 56: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 665
Table 57: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Acute Myelogenous Leukemia 666
Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 667
Table 59: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Adrenal Cancer 668
Table 60: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of B-cell Lymphoma 669
Table 61: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 670
Table 62: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Basal Cell Cancer 671
Table 63: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Biliary Cancer 672
Table 64: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Bladder Cancer 673
Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 674
Table 66: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Bone Cancer 675
Table 67: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Brain Cancer 676
Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 677
Table 69: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Breast Cancer 678
Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 680
Table 71: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Cancer (general) 681
Table 72: Target Strategy Development Profiles of Apoptotic Drugs for Cancer Diagnosis 682
Table 73: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Carcinoid 683
Table 74: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Cervical Cancer 684
Table 75: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Cervical Dysplasia 685
Table 76: Target Strategy Development Profiles of Apoptotic Drugs as Chemopreventative 686
Table 77: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Chemotherapy-induced Pain 687
Table 78: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Chronic Lymphocytic Leukemia 688
Table 79: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 690
Table 80: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Chronic Myelogenous Leukemia 691
Table 81: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 692
Table 82: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Chronic Myelomonocytic Leukemia 693
Table 83: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Colorectal Cancer 694
Table 84: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 696
Table 85: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Endometrial Cancer 697
Table 86: The Competition through Close Mechanistic Approximation between Benign Endometrial Cancer Drugs 698
Table 87: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Fallopian Tube Cancer 699
Table 88: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Fibro Sarcoma 700
Table 89: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Cancer (general) 701
Table 90: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stomach Cancer 702
Table 91: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stromal Cancer 704
Table 92: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Head and Neck Cancer 705
Table 93: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 706
Table 94: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Hematological Cancer (general) 707
Table 95: The Competition through Close Mechanistic Approximation between Hematological Cancer (general) Drugs 707
Table 96: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Hodgkin’s Lymphoma 708
Table 97: The Competition through Close Mechanistic Approximation between Hodgkin’s Lymphoma Drugs 709
Table 98: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Leiomyo Sarcoma 710
Table 99: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Leukemia (general) 711
Table 100: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Lipo Sarcoma 712
Table 101: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Liver Cancer 713
Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 714
Table 103: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Lung Cancer (general) 715
Table 104: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 717
Table 105: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Lymphoma (general) 718
Table 106: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 719
Table 107: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Mastocytosis 720
Table 108: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Melanoma 721
Table 109: The Competition through Close Mechanistic Approximation between Melanoma Drugs 723
Table 110: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Mesothelioma 724
Table 111: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 724
Table 112: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Myelodysplastic Syndrome 725
Table 113: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 726
Table 114: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Myeloma 727
Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs 729
Table 116: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Nasopharyngeal Cancer 730
Table 117: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Neuroblastoma 730
Table 118: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Neuroendocrine Cancer (general) 731
Table 119: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of non-Hodgkin’s Lymphoma 732
Table 120: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 734
Table 121: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Non-Small Cell Lung Cancer 735
Table 122: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 737
Table 123: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Oesophageal Cancer 738
Table 124: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Oral Cancer 739
Table 125: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Osteo Sarcoma 740
Table 126: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Ovarian Cancer 741
Table 127: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 743
Table 128: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Pancreatic Cancer 744
Table 129: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 746
Table 130: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Peritoneal Cancer 747
Table 131: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Prostate Cancer 748
Table 132: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 750
Table 133: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 752
Table 134: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Radio/chemotherapy-induced Anemia 752
Table 135: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 753
Table 136: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Renal Cancer 754
Table 137: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 756
Table 138: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Rhabdomyo Sarcoma 757
Table 139: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Sarcoma (general) 758
Table 140: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Small Cell Lung Cancer 760
Table 141: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 761
Table 142: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Soft Tissue Sarcoma 762
Table 143: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 763
Table 144: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Solid Tumor 764
Table 145: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 765
Table 146: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Squamous Cell Cancer 766
Table 147: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma 767
Table 148: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Testicular Cancer 768
Table 149: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Thymoma Cancer 769
Table 150: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Thyroid Cancer 770
Table 151: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 771
Table 152: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Unspecified Cancer Indication 772
Table 153: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 774
Table 154: Target Strategy Development Profiles of Apoptotic Drugs for the Treatment of Waldenstrom’s hypergammaglobulinemia 776
Table 155: Competitive Summary by Investigator of Apoptotic Drug Development 777
Table 156: Summary Table of Corporate Changes in the Competitive Landscape of Apoptotic Drug Development in Oncology 781
Table 157: Example of a Competitive Fall-Out Table (Targeting TNFRSF10A/Modified) 789
Table 158: Abbott’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 793
Table 159: Access’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 798
Table 160: Advanced Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 802
Table 161: AEgera’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 807
Table 162: AEterna Zentaris’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 815
Table 163: Aida Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 822
Table 164: Aileron Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 826
Table 165: Alnylam’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 830
Table 166: Ambrilia Biopharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 834
Table 167: Amgen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 839
Table 168: Anadys Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 845
Table 169: Anaphore’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 850
Table 170: Anavex Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 855
Table 171: Antisoma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 861
Table 172: Aphios’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 866
Table 173: Apogenix’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 870
Table 174: ApopLogic Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 875
Table 175: Arno Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 881
Table 176: ArQule’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 886
Table 177: Ascenta Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 894
Table 178: Astex Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 899
Table 179: AstraZeneca’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 903
Table 180: Attenuon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 908
Table 181: Avila Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 912
Table 182: Basilea Pharmaceutica’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 917
Table 183: Bayer’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 925
Table 184: BioAlliance Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 931
Table 185: BioAxone’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 935
Table 186: Biocad’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 940
Table 187: Biogen Idec’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 946
Table 188: BioInvent’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 951
Table 189: BioLineRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 955
Table 190: Biomas’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 959
Table 191: Bionovo’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 963
Table 192: BioVex’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 967
Table 193: Boehringer Ingelheim’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 972
Table 194: Bristol-Myers Squibb’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 977
Table 195: Cancer Research Technology’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 982
Table 196: CDG Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 986
Table 197: Celera’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 990
Table 198: Cephalon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 995
Table 199: ChemoCentryx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 999
Table 200: Chlorogen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1003
Table 201: Chroma Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1007
Table 202: Cleveland BioLabs’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1011
Table 203: CombinatoRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1017
Table 204: Coronado Biosciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1022
Table 205: Critical Outcome Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1027
Table 206: Curis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1031
Table 207: Cyclacel’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1036
Table 208: Cylene Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1042
Table 209: Cynvec’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1046
Table 210: CytImmune Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1051
Table 211: Cytochroma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1056
Table 212: CytRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1060
Table 213: Daewoong’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1064
Table 214: Daiichi Sankyo’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1069
Table 215: Dainippon Sumitomo Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1074
Table 216: DeveloGen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1079
Table 217: Eisai’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1085
Table 218: Eleos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1089
Table 219: Eli Lilly’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1094
Table 220: Emergent BioSolutions’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1100
Table 221: EntreMed’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1105
Table 222: EpiCept’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1112
Table 223: Erimos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1119
Table 224: Exelixis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1124
Table 225: Genta’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1130
Table 226: Gerolymatos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1135
Table 227: Geron’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1140
Table 228: GlaxoSmithKline’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1145
Table 229: GlycoGenesys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1152
Table 230: Glycotope’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1156
Table 231: GPC Biotech’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1160
Table 232: Green Cross’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1164
Table 233: Harbor BioSciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1168
Table 234: Hoffmann-La Roche’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1173
Table 235: Human Genome Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1179
Table 236: Idera Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1185
Table 237: Infinity Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1190
Table 238: Innate Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1195
Table 239: InNexus Biotechnology’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1200
Table 240: Inovio’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1204
Table 241: Insmed’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1208
Table 242: Insys Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1212
Table 243: Intradigm’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1216
Table 244: Introgen Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1221
Table 245: Isis Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1226
Table 246: ISU ABXIS’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1230
Table 247: Johnson & Johnson’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1235
Table 248: Kalypsys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1243
Table 249: Keryx Biopharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1250
Table 250: Kyowa Hakko Kirin’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1256
Table 251: Leo’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1261
Table 252: Ligand’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1266
Table 253: Lorus Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1270
Table 254: Medisyn Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1274
Table 255: Merck & Co’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1278
Table 256: MethylGene’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1283
Table 257: Nereus Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1288
Table 258: Nerviano Medical Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1292
Table 259: NIH’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1296
Table 260: Nippon Shinyaku’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1301
Table 261: Non-industrial source’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1305
Table 262: Novacea’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1310
Table 263: NovaLead’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1315
Table 264: Novartis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1323
Table 265: Novelix’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1337
Table 266: Novogen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1342
Table 267: Onconova’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1349
Table 268: Oncothyreon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1355
Table 269: OSI Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1360
Table 270: OXiGENE’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1366
Table 271: PanaGin’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1370
Table 272: Patrys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1374
Table 273: Pfizer’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1379
Table 274: Pharmacyclics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1386
Table 275: PharmaMar’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1392
Table 276: Pharminox’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1398
Table 277: Pierre Fabre’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1402
Table 278: ProMetic Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1407
Table 279: QLT’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1413
Table 280: Reata Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1420
Table 281: Regulon’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1426
Table 282: Rigel’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1431
Table 283: Rosetta Genomics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1436
Table 284: Sanofi’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1441
Table 285: Santaris Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1447
Table 286: SBI Biotech’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1453
Table 287: Seattle Genetics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1458
Table 288: Semafore Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1463
Table 289: Senesco Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1467
Table 290: Sigma-Tau’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1472
Table 291: SRI International’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1477
Table 292: SuperGen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1483
Table 293: Switch Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1489
Table 294: SymBio Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1493
Table 295: Symbiotec’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1497
Table 296: Takeda’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1502
Table 297: Taxolog’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1509
Table 298: Telik’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1515
Table 299: TetraLogic Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1519
Table 300: Teva’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1523
Table 301: Thallion Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1527
Table 302: Tigris Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1532
Table 303: TopoTarget’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1539
Table 304: Tracon Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1547
Table 305: UMN Pharma’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1552
Table 306: ValiRx’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1557
Table 307: VBL Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1562
Table 308: Velacor Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1566
Table 309: Vertex Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1570
Table 310: Vical’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1574
Table 311: VioQuest’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1579
Table 312: Viragen’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1584
Table 313: Viralytics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1588
Table 314: ViroTarg’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1593
Table 315: VM Discovery’s Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 1598

This report includes 158 companies (Incl. Out of Business ones) plus their collaborators:
Abbott
Access
Advanced Life Sciences
AEgera
AEterna Zentaris
Aida Pharmaceuticals
Aileron Therapeutics
Alnylam
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Arno Therapeutics
ArQule
Ascenta Therapeutics
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Bayer
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
BioLineRx
Biomas
Bionovo
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Research Technology
CDG Therapeutics
Celera
Cephalon
ChemoCentryx
Chlorogen
Chroma Therapeutics
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Critical Outcome Technologies
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
DeveloGen
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
EpiCept
Erimos
Exelixis
Genta
Gerolymatos
Geron
GlaxoSmithKline
GlycoGenesys
Glycotope
GPC Biotech
Green Cross
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intradigm
Introgen Therapeutics
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kalypsys
Keryx Biopharmaceuticals
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
Medisyn Technologies
Merck & Co
MethylGene
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Onconova
Oncothyreon
OSI Pharmaceuticals
OXiGENE
PanaGin
Patrys
Pfizer
Pharmacyclics
PharmaMar
Pharminox
Pierre Fabre
ProMetic Life Sciences
QLT
Reata Pharmaceuticals
Regulon
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
SBI Biotech
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Sigma-Tau
SRI International
SuperGen
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Takeda
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Tigris Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
UMN Pharma
ValiRx
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
VioQuest
Viragen
Viralytics
ViroTarg
VM Discovery
This report includes 234 apoptotic drugs in cancer. From Ceased to Marketed. Some examples are:
131I-tositumomab
AEG-35156
alvocidib
AME-133
APG-101
ARQ-197
AS-101
AS-1411
bardoxolone methyl
belinostat
bortezomib
bosutinib
BZL-101
canfosfamide hydrochloride
cenersen
cintredekin besudotox
conatumumab
crolibulin
dinaciclib
dulanermin
enzastaurin hydrochloride
fosbretabulin tromethamine
gataparsen
GT-111
HE-3235
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imetelstat
kahalalide F
lestaurtinib
litronesib
lonaprisan
lumiliximab
mapatumumab
MKC-1
mocetinostat
motexafin gadolinium
navitoclax
noscapine
obinutuzumab
oblimersen sodium
ON-01910
Oncohist
panobinostat
PAT-SC1
PBI-1402
PCI-24781
plitidepsin
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
retaspimycin
sagopilone
seliciclib
SPC-2996
ß-lapachone
SU-6668
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
triciribine phosphate
TRU-016
volasertib
vosaroxin
XL-147
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others.
    To find out more about Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Protein Kinase Therapeutics in Oncology - Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Leukemia and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Prostate Cancer. Learn More


Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Learn More